Hortaleza A R, Salta-Ramos N G, Barcelona-Tan J, Abad-Venida L
Department of Dermatology, Jose R. Reyes Memorial Medical Center, Manila, Philippines.
Lepr Rev. 1995 Dec;66(4):307-13. doi: 10.5935/0305-7518.19950034.
A case of dapsone syndrome occurring in a Filipino man under treatment for multibacillary (MB) leprosy is described. The patient manifested progressive fever, erythroderma and jaundice 4 weeks after initiation of multidrug therapy (MDT) with rifampicin, clofazimine and dapsone. The clinical symptoms conformed well to the dapsone syndrome first described in the 1950s and this report proves that the syndrome does still exist. There was recovery after dapsone was omitted and therapy with systemic corticosteroids was started. In view of this potentially fatal hypersensitivity reaction, this case report emphasizes the need for caution when initiating MDT or dapsone therapy. It is also suggested that any patient on MDT or dapsone needs to be referred immediately to a dermatologist or internist if the patient develops a skin rash during the first 2 months of treatment.
本文描述了一例在接受多菌型(MB)麻风病治疗的菲律宾男性中发生的氨苯砜综合征病例。该患者在开始使用利福平、氯法齐明和氨苯砜进行多药联合治疗(MDT)4周后,出现进行性发热、红皮病和黄疸。临床症状与20世纪50年代首次描述的氨苯砜综合征高度相符,本报告证明该综合征仍然存在。停用氨苯砜并开始使用全身性皮质类固醇治疗后病情恢复。鉴于这种潜在的致命性过敏反应,本病例报告强调在开始MDT或氨苯砜治疗时需要谨慎。还建议,如果任何接受MDT或氨苯砜治疗的患者在治疗的前2个月内出现皮疹,应立即转诊至皮肤科医生或内科医生处。